Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas — Baltimore experiences

George W. Santos, R. Saral, W. H. Burns, H. G. Braine, L. L. Sensenbrenner, J. R. Wingard, A. M. Yeager, R. Jones, R. F. Ambinder, S. D. Rowley, S. May, G. B. Vogelsang

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Allogeneic bone marrow transplants (BMT) in acute lymphoblastic leukemia following cyclophosphamide (Cy) and total body irradiation (TBI) has resulted in disease-free survival (DFS) for CR1, CR2, and CR3 of 10/18 (56%), 16/30 (53%) and 4/17 (24%), respectively. Median follow-up of survivors was 25-43 months. One relapse was seen in CR1, 1 in CR2, and 6 in CR3. Allogeneic BMT in acute nonlymphoblastic leukemia (ANLL) following busulfan (Bu) resulted in DFS for CR1, CR2 + CR3 + early relapse of 21/47 (45%) and 13/41 (32%), respectively. Median DFS of survivors of all groups together was 36 months. DFS of all patients 20 years or less was 15/27 (56%) and 19/61 (31%) for ages 21-46. Three relapses of 47 (6%) were seen in CR1 and 6/41 (15%) in subsequent remission and early relapse. BMT of autologous BMT with 4-hydroperoxy- cyclophosphamide (4-HC) purged marrow in ANLL in CR1 (5), CR2 (32) and CR3 (9) following Bu + Cy resulted in DFS of 19/46 (41%) for 1-67 months (median 15 months). Twenty patients with prior risk non- Hodgkin’s lymphoma received 4-HC-purged marrow following Cy +TBI. DFS was 10/20 (50%) for 1.4-9.5 years (median 2.9 years).

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalActa Haematologica
Volume78
DOIs
StatePublished - 1987
Externally publishedYes

Keywords

  • Acute leukemias
  • Bone marrow transplantation
  • Lymphomas

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas — Baltimore experiences'. Together they form a unique fingerprint.

Cite this